secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001104659-25-086428
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter to Outlook Therapeutics for ONS-5010 BLA; lacks efficacy evidence
--------------------------------------------------------------------------------

- CRL cites lack of substantial evidence of effectiveness; ONS-5010 did not meet primary endpoint in NORSE EIGHT trial.
- FDA recommends confirmatory evidence; NORSE TWO met primary endpoint but is not sufficient alone.
- No other deficiencies in BLA; company plans to meet with FDA to discuss possible path to approval.
- ONS-5010/LYTENAVA already approved in EU and UK; commercial launch in Germany and UK began June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925086428/0001104659-25-086428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925086428/tm2524956d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-086428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer